Visirna Therapeutics
Signal active
Organization
Contact Information
Overview
Arrowhead and Vivo formed Visirna Therapeutics as a joint venture to bring four of the biotech's RNAi therapies to China. Through a licensing agreement, the company will focus on four of Arrowhead's therapies for cardiometabolic diseases.
About
Industries
Biotechnology, Health Care, Medical, Therapeutics
Founded
2022
Employees
0
Headquarters locations
Asia
Social
N/A
Profile Resume
Visirna Therapeutics headquartered in Asia, operates in the Biotechnology, Health Care, Medical, Therapeutics sector. The company focuses on Biotechnology and has secured $960.0M in funding across 16 round(s). Their latest funding round, Seed Round - Visirna Therapeutics, raised $60.0M. Discover more about their projects, partnerships, and impact on our platform.
Employees
N/A
Funding Rounds
Funding rounds
1
Investors
1
Lead Investors
0
Total Funding Amount
$60.0M
Details
1
Visirna Therapeutics has raised a total of $60.0M in funding over 1 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2022 | Seed | 60.0M |
Investors
Visirna Therapeutics is funded by 4 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Hongbo Lu | - | FUNDING ROUND - Hongbo Lu | 60.0M |
| Gaurav Aggarwal | - | FUNDING ROUND - Gaurav Aggarwal | 60.0M |
| Visirna Therapeutics | - | FUNDING ROUND - Visirna Therapeutics | 60.0M |
| Vivo Capital | - | FUNDING ROUND - Vivo Capital | 60.0M |
Recent Activity
There is no recent news or activity for this profile.